- Home
- FTHM vs CGTX Comparison
FTHM vs CGTX Comparison
Compare FTHM & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHM | CGTX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 94.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FTHM | CGTX |
|---|---|---|
| Price | $0.77 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.50 | ★ $3.33 |
| AVG Volume (30 Days) | 78.7K | ★ 595.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $335,184,000.00 | N/A |
| Revenue This Year | $30.07 | N/A |
| Revenue Next Year | $14.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.65 | $0.22 |
| 52 Week High | $3.37 | $3.83 |
Technical Indicators
Market Signals| Indicator | FTHM | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 50.88 |
| Support Level | $0.70 | $1.00 |
| Resistance Level | $1.49 | $1.19 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 39.80 | 65.61 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.